tradmap

IDXX Idexx Laboratories

$529.17 -1.81%

Updated

Nasdaq 100 CompaniesS&P 500 Companies

Held by SPYVOOIVVQQQQQQM

Healthcare · In Vitro & In Vivo Diagnostic Substances

Idexx Laboratories (IDXX) is a healthcare company in the In Vitro & In Vivo Diagnostic Substances industry, with a market capitalization of $41.7 billion. Shares last traded at $529.17, 31.2% below their 52-week high. Over the past year the stock is down 18.2%. IDXX trades at a price-to-earnings ratio of 36.58, in line with the In Vitro & In Vivo Diagnostic Substances median of 36.58. Net profit margin is 25.0%, above the peer median of -0.9%. Revenue grew 10.4% year over year.

Market Cap
$41.7B
Shares Out
78.8M
EPS (TTM)
$27.79
P/E Ratio
19.04
P/S Ratio
9.16
P/B Ratio
25.85
Dividend / Share
Dividend Yield
52-Week High
$769.08
52-Week Low
$519.58
Volume
54,089
Avg Vol (3m)
44,173.571

Performance

1W
-2.91%
1M
-9.49%
3M
-3.90%
6M
-16.72%
YTD
-21.06%
1Y
-18.23%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
38.03
SMA (50)
$558.56
SMA (200)
$609.20
Price vs SMA50
-5.26%
Price vs SMA200
-13.14%
ATR (14)
$16.86

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$4.6B
Net Income
$1.1B
Gross Margin
62.4%
Operating Margin
32.0%
Net Margin
25.0%
Return on Equity
70.7%
Return on Assets
33.1%
Current Ratio
1.17
Debt / Equity
0.19
Revenue Growth (YoY)
+10.4%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $7.74 2026-08-04
Q1 2026 $3.47 2026-05-05
FY 2025 $13.08 2026-02-20
Q3 2025 $9.99 2025-11-03
Q2 2026 $6.59 2026-08-04
Q1 2026 $2.96 2026-05-05

Full earnings history →

In Vitro & In Vivo Diagnostic Substances peers

IDXX vs 14 industry peers (In Vitro & In Vivo Diagnostic Substances), by market cap. Updated

P/E vs peers
36.58 / 36.58 med
+0% premium
P/S vs peers
9.16 / 4.24 med
+116% premium
Net margin vs peers
25.0% / -0.9% med
above median
1–14 of 14
IDXXIdexx Laboratories$41.7B36.589.1625.0%-1.81%
LNTHLantheus Holdings, Inc.$6.6B23.944.2417.7%+0.17%
CLDXCelldex Therapeutics, Inc.$3.1B-10.282000.34-0.32%
NEOGNeogen Corp$2.5B-322.002.92-0.9%-1.36%
NTLAIntellia Therapeutics, Inc.$1.8B-4.44-0.63%
QDELQuidelortho Corp$955M-0.910.36-39.2%-0.11%
ACHVAchieve Life Sciences, Inc.$855M-7.49-2.18%
TKNOAlpha Teknova, Inc.$388M-23.128.87-38.4%-2.83%
MYGNMyriad Genetics Inc$309M-2.740.38-14.0%-0.31%
IMDXInsight Molecular Diagnostics Inc.$135M-2.7433.41+2.99%
ICCCIMMUCELL CORP /DE/$90M114.192.932.6%-0.35%
QCLSQ/C TECHNOLOGIES, INC.$15M-0.939.79-1.57%
BMRABIOMERICA INC$10M-2.732.31-84.8%+2.51%
CDIOCardio Diagnostics Holdings, Inc.$5M-0.84374.80-1.08%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.